More on MIST
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.07 |
|
|||
| Open | $1.07 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $1.08 | ||||
| Day Low | $1.06 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 396,325 | ||||
- H.C. Wainwright Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
- Milestone study finds PSVT impacts patient life between episodes
- Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
- Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
- Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
- Form 8-K Milestone Pharmaceutical For: Aug 12
- Milestone Pharmaceuticals Inc. (MIST) Misses Q2 EPS by 2c
- Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- Form 10-Q Milestone Pharmaceutical For: Jun 30
Entities mentioned with MIST
- FDA | View Related Stories »
- Twitter | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
